Newman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
February 14 2017 - 12:40PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Dimension
Therapeutics Inc. (“Dimension” or the “Company”) (NASDAQ:DMTX) into
potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
Dimension, headquartered in Cambridge, MA, is a company focused
on developing therapeutic gene therapies for people living with
rare liver diseases caused by genetic mutations. Newman Ferrara’s
investigation focuses on decisions made by the Board, without
shareholder approval, the result of which significantly diminish
shareholder value and do not benefit the Company. Considering the
Company’s lackluster performance since its October 2015 IPO, it is
clear that the Board lacks the ability to fairly assess and oversee
the Company’s direction and leadership.
Current Dimension stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com)
to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170214006143/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024